SCHEDULE: TPG Discloses 29.3% Stake in LifeStance Health

TPG GP A, LLC and its principals report a 29.3% beneficial ownership stake in LifeStance Health Group, Inc. via an amended Schedule 13G filing.

Summary

• TPG GP A, LLC, James G. Coulter, and Jon Winkelried filed an Amendment No. 2 to Schedule 13G regarding their holdings in LifeStance Health Group, Inc.
• The reporting persons beneficially own 111,744,614 shares of common stock.
• This ownership represents 29.3% of the total outstanding common stock, based on 381,834,432 shares outstanding as of May 12, 2026.
• The reporting persons share voting and dispositive power over these shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral regulatory disclosure confirming the status quo of institutional ownership without signaling new strategic shifts or financial distress.

Positives

• Maintains significant institutional backing from a major private equity firm.
• Clear disclosure of beneficial ownership structure and voting agreements.

Negatives

• Concentrated ownership by a single private equity group may influence corporate governance and strategic direction.

Risks

• Potential for market volatility if the reporting persons decide to divest a portion of their significant 29.3% stake.
• Voting agreements with other holders could lead to conflicts of interest or influence board composition in ways not aligned with all shareholders.

Future Outlook

The filing does not provide specific forward-looking guidance regarding the company's operations, but confirms the ongoing participation of TPG in the governance of LifeStance Health through existing stockholders agreements.

Management Comments

• The reporting persons disclaim beneficial ownership of shares held by other parties to the Stockholders Agreement, except to the extent of their pecuniary interest.

Industry Context

StockSavvy.ai notes that large-scale private equity ownership in healthcare services companies like LifeStance is common, often signaling long-term strategic involvement in scaling operations, though it can create overhang concerns for retail investors.

Comparison to Industry Standards

• The 29.3% stake is consistent with typical 'significant shareholder' thresholds for private equity firms in mid-cap healthcare companies.
• The use of a Schedule 13G (rather than 13D) suggests the reporting persons are maintaining a passive investment stance relative to active control, despite the existence of a stockholders agreement.

Corporate Governance

Stakeholder Impact

• Shareholders should be aware of the significant voting block controlled by TPG.
• The stability of the board is tied to the ongoing participation of the reporting persons.

Next Steps

• Continued monitoring of TPG's holdings for any future changes in ownership or divestment activity.

Key Dates

Keywords

LifeStance Health, TPG, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock